Skip to main content
Patient preference and adherence logoLink to Patient preference and adherence
. 2025 Apr 2;19:883–896. doi: 10.2147/PPA.S509263

Who is Seeking Traditional Chinese Medicine (TCM) for Cancer? Insights from a Large Cohort in a Rehabilitation Clinic

Yong Zhang 1,*, Yiding Dai 2,3,*, Dan Kang 1,*, Qingsong Yu 4, Xiangxi Zhou 1, Xin Tian 1, Qiulong Chen 5, Yi Chen 6, Fang Liu 2, Qiuling Shi 1,3,
PMCID: PMC11972600  PMID: 40190445

Abstract

Purpose

Traditional Chinese Medicine (TCM) is widely used in cancer care, yet its utilization features are not well understood. By providing a comprehensive overview of the demographic and clinical characteristics, symptom burden, HRQoL, and TCM constitution of cancer patients seeking TCM treatment, we aim to offer insights into the integration of TCM into cancer care.

Patients and Methods

The questionnaire collected data on demographic and clinical characteristics, the MD Anderson Symptom Inventory for Traditional Chinese Medicine (MDASI-TCM), the EuroQol-5Dimensions-5Levels (EQ-5D-5L), and the simplified version of the Constitution in Chinese Medicine Questionnaire (CCMQ). A descriptive analysis was conducted to profile the patients’ status and expectations of TCM. Chi-square or Fisher exact tests were employed to compare the distribution of TCM constitutional types across different cancer diagnoses.

Results

Among 3047 eligible patients, 2796 (median age 55) completed the questionnaire and were subsequently included in the analysis. The cohort was predominantly female (56.5%), with lung cancer being the most common primary diagnosis (25.2%). Furthermore, 86.7% of the patients presented with a good performance status (ECOG-PS ≤ 1). The main reasons patients sought TCM treatment were to alleviate cancer-related symptoms (59.4%) and enhance immune function (55.4%). The most prevalent symptoms (scored 1–10 on a 0–10 scale) were fatigue (81.1%), followed by disturbed sleep (81.0%), and dry mouth (78.2%). The mean and median EQ-5D-5L utility scores were 0.81 and 0.89, respectively. About 83.4% of cancer patients exhibited a deviation in TCM constitution, with Yang-deficiency being particularly common among them.

Conclusion

This study highlights the symptom burden, HRQoL, TCM constitution, and characteristics of patients who pursue TCM treatment. It advances our understanding of TCM’s role in cancer rehabilitation by shedding light on target population potential needs of care. The findings provide a foundation for developing evidence-based strategies to enhance TCM application in clinical settings, optimize resource allocation, and improve rehabilitation outcomes for cancer patients.

Keywords: traditional Chinese medicine, patient-reported outcomes, symptom burden, health-related quality of life, TCM constitution, cancer rehabilitation

Introduction

The 2022 Global Cancer statistics indicate approximately 20 million new cancer cases and nearly 10 million cancer-related deaths, the top three types were lung cancer (12.4%), female breast cancer (11.5%), and colorectal cancer (9.6%).1 China leading globally in both the incidence and mortality rates of cancer. Cancer treatments have long focused on surgery, radiation therapy, chemotherapy and targeted therapy, etc.2 Despite achieving radical or temporary tumor control, cancer survivors continue to experience a substantial symptom burden resulting from both the disease itself and treatment-induced adverse effects.3,4 Symptoms can be acute, manifesting during treatment, but may also involve long-term and late effects, with approximately one-third of cancer survivors receiving treatment reporting three or more moderate-to-severe symptoms.5 The symptom burden is particularly pronounced in patients with advanced or metastatic cancer. Although effective symptom management through symptom monitoring can enhance health-related quality of life (HRQoL), mitigate treatment-related toxicities, and potentially improve overall survival,6,7 many patients continue to report undertreatment or non-treatment of symptoms with conventional cancer therapies.8 An increasing number of cancer patients are turning to complementary and alternative medicine (CAM) as part of supportive care for symptom management.9

CAM includes traditional herbal medicine, acupuncture, massage, and music therapy, among others, which originated in countries such as China, Rome, and India.10 Compared to other CAMs, Traditional Chinese Medicine (TCM) is deeply rooted in Chinese culture and is an important part of the traditional culture of the Chinese nation.11 Over thousands of years, TCM has developed a distinct theoretical framework, diagnostic methods, and therapeutic approaches in Asian countries, and especially China.12 Therefore, cancer patients are more likely to accept TCM for symptom management, making it mainstream. In China, 53% to 83% of cancer patients use TCM during cancer treatments,13–15 and 94.6% of cancer patients express a willingness to incorporate TCM into their treatment regimen.16 Furthermore, many cancer hospitals have integrated TCM care into their service offerings, which improved accessibility to TCM for cancer patients. A substantial body of research has demonstrated that TCM not only alleviates clinical symptoms in cancer patients and boosts the immune system but also mitigates the adverse effects and complications associated with radiotherapy, chemotherapy, or targeted therapy.12,17–19 The effects are mainly attributed to the active ingredients in TCM, such as ginsenosides in Panax ginseng, which have been found to have anti-inflammatory, antioxidant, and anticancer actions,20 and saponins and flavonoids in Astragali radix contribute to anticancer and immunomodulatory actions.21 Although some Chinese medicines contain toxic ingredients, their use, dosage, and treatment cycle are carefully controlled to minimize side effects and toxicity.22 Notably, acupuncture has been shown to be particularly effective in managing common cancer-related symptoms such as pain, nausea and vomiting, fatigue, dry mouth, peripheral neuropathy, and sleep disturbances.23–25 Other benefits of TCM include reducing the likelihood of tumor recurrence and metastasis, with a low incidence of adverse events.18

The concept of cancer rehabilitation within TCM has been introduced in recent years, garnering significant attention for its perceived effectiveness in the rehabilitation field.16 However, as an emerging field, securing effective resource allocation and determining appropriate TCM service for patients necessitate careful consideration and systematic planning. Although the prevalence, patterns, and barriers to integrating CAM into cancer patient care have been well-documented,26–29 few studies have investigated the critical factors in health system management, such as the demographic and disease characteristics, symptom burden, HRQoL and TCM constitution of patients seeking TCM services in cancer hospital settings. Even if there are articles about it, they often focus solely on specific treatments like acupuncture or specific cancer types such as lung cancer.30,31 To bridge this knowledge gap, we analyzed the baseline data of a prospective cohort, which was continuously recruiting patients from the TCM rehabilitation clinic in a cancer hospital. This study sought to identify the demographic and clinical characteristics, as well as the motivations of cancer patients seeking TCM treatment, to provide a comprehensive understanding of their symptom burden, HRQoL, and TCM constitution.

Materials and Methods

Setting and Participants

We extracted baseline data from an ongoing prospective cohort study for analysis. Participants were cancer patients who sought TCM treatment at the TCM Rehabilitation Department of Sichuan Cancer Hospital (the largest cancer hospital in Southwest China) from September 2021 to July 2024. Eligible patients were aged over 18 years and had a definite current or past diagnosis of cancer. Patients with cognitive impairments, communication difficulties, refusal, or physical weakness preventing them from completing the questionnaire were excluded. Participants were instructed to complete the survey independently. In cases of difficulty completing the scales, investigators or designated proxies assisted participants by reading each item aloud and recording their responses. Ethics approval for the study was granted by the Ethics Committee for Medical Research and New Medical Technology of Sichuan Cancer Hospital (Approval Number: SCCHEC-02-2021-048 and KY-2021-004-03). All participants provided informed consent. The study complies with the Declaration of Helsinki.

Treatment Procedure

The content of treatment mainly included two modules: Chinese herbal medicine (CHM) therapies and acupuncture intervention. CHM therapies adhered to TCM syndrome differentiation principles, emphasizing health strengthening (Fu-Zheng) and pathogen elimination (Qu-Xie). TCM physicians prescribe a combination of different herbs tailored to each patient diagnosed with individualized TCM syndromes based on symptoms and observations of tongue and pulse. For the acupuncture intervention, acupoints were tailored to the presentation of the individual and selected based on the theory of TCM, patient-reported symptoms, and the expertise of TCM-trained acupuncturists. Needles were manually manipulated to achieve the “De Qi” sensation, and retained for 30 minutes.32 Patients were monitored for potential side effects during each visit. All participating TCM physicians and acupuncturists were certified professionals, with a minimum of 10 years of experience in oncology and extensive training in the study protocol.

Study Measures

Patients received a paper-based questionnaire during their visits. Data on general demographic and disease-related characteristics were collected. Demographic data included sex, age, body mass index (BMI), education level, comorbidities, etc. The latter included cancer diagnosis, Eastern Cooperative Oncology Group score (ECOG-PS), and historical treatments received.

Patients were invited to complete the MD Anderson Symptom Inventory for Traditional Chinese Medicine (MDASI-TCM), the EuroQol-5Dimensions-5Levels (EQ-5D-5L), and the Constitution in Chinese Medicine Questionnaire (CCMQ) either by the receptionist or the clinician before their treatment. Patients with TCM consultation records but no MDASI-TCM or CCMQ data would be excluded.

Since symptoms are a primary reason for patients with cancer to seek TCM,29 we selected MDASI-TCM as the patient-reported outcome measure (PROM) to assess both disease- and treatment-related symptoms, as well as those commonly addressed in TCM practice. MDASI-TCM is a widely utilized PROs instrument designed to assess symptoms experienced by cancer patients who opt for TCM. The Chinese version of the MDASI-TCM has been psychometrically and clinically validated.33 It comprises 13 core symptoms, 7 symptoms specific to TCM practices, and 6 interference items. Each item is rated on a 0–10 scale, where 0 denotes “Not Present” and 10 denotes “As Bad As You Can Imagine”.34,35 The total interference score is a composite endpoint of six items, assessing the extent to which symptoms interfere with affective (REM: social relationships, enjoyment of life, mood) and physical (WAW: walking, general activity, work) components. Patient-reported scores were classified as none (0), mild (1–3), moderate (4–6), or severe (7–10) symptom burden/interference.36

EQ-5D-5L is a multidimensional measure of HRQoL that includes five domains to describe patients’ health: (1) mobility; (2) self-care; (3) usual activities; (4) pain/discomfort; and (5) anxiety/depression, with a scale ranging from 0 (no difficulty) to 4 (extreme difficulty). The Chinese version of the EQ-5D-5L has been validated.37 Health utility values are derived from the Chinese EQ-5D-5L Value Set.38 Another component of the EQ-5D-5L, the EQ Visual Analogue Scale (EQ-VAS), enables patients to assess their current health status on a scale from 0 (the worst health state they can imagine) to 100 (the best health state they can imagine).

Constitution is formed under the influence of innate endowment inheritance and acquired environment. The constitution of different individuals has certain differences. According to the theory of TCM constitution, individuals can be categorized into nine distinct constitutional types: one balanced constitution (Gentleness) and eight imbalanced constitutions (Yang-deficiency, Yin-deficiency, Phlegm-dampness, Qi-deficiency, Damp-heat, Blood-stasis, Depressive, and Inherited special constitution). The simplified version of the CCMQ was utilized to assess and classify the participants’ TCM constitutional types.39 Each type of constitution corresponds to a subscale, measuring items in five-level ratings from “none” to “always”, with the raw scores and converted scores calculated from one formula. Specifically, the conversion score is defined as [(original score − number of entries) / (number of entries×4)]×100. A balanced constitution is identified if the subscale score for this constitution is greater than or equal to 60, while all other eight subscales score less than 40. If the score of any other unbalanced constitution reaches 40, the constitution is determined as the type the individual belongs to.

Statistical Analysis

Patients who provided complete demographic and clinical information and achieved completion rate were included in the analysis. The completion rate was calculated, with the MDASI-TCM completion defined as successfully answering 80% or more of the questionnaire items (21 out of 26). The top three imbalanced TCM Constitutional types were those with the highest rate in each cancer type. Descriptive statistics were utilized to summarize the demographic and clinical characteristics, PROs, and TCM constitutional types. Continuous variables were expressed as either the mean and standard deviation (SD) or the median with interquartile range (IQR), whereas categorical variables were presented as absolute frequencies and percentages. The differences in TCM constitutional types among various cancer diagnoses were evaluated using the χ2 test, and the P value calculation that did not meet the χ2 test conditions used Fisher’s exact test. Differences were deemed statistically significant if the two-tailed P-values were <0.05. All data analyses were conducted using SAS V.9.4 (SAS Institute).

Results

Baseline Demographic and Disease-Related Characteristics

A total of 3047 patients sought TCM treatment from September 2021 to July 2024. Demographic and clinical data at baseline were missing for 167 patients, and an additional 84 patients were excluded for not achieving an 80% completion rate in questionnaires. Consequently, 2796 patients (91.8%) consented to PROs collection and met the inclusion criteria for study analysis. The demographic and clinical characteristics of these patients are detailed in Table 1. Cancer patients attending the TCM rehabilitation clinic were predominantly female, with a median (IQR) age of 55 (49–64) years. 396 patients (14.2%) were aged 70 years or older (median, 74 years), 20.6% were between 60 and 69 years (median, 65 years), 38.8% were between 50 and 59 years (median, 55 years), and 26.4% were younger than 50 years (median, 44 years). Among the patients included in the study, 91.0% were married. The majority (72.6%) reported having received at least a middle or high school education and 16.4% of patients were employed full-time. Lung cancer was the most prevalent diagnosis (25.2%), followed by gynecological (13.5%), breast (13.0%), nasopharyngeal (8.6%), and colorectal (8.3%). 86.7% of the patients presented with good performance status (ECOG-PS≤1). The primary purposes for patients seeking TCM treatment were to alleviate cancer-related symptoms (59.4%) and boost the immune system (55.4%). Most cancer patients had completed conventional anticancer therapies before receiving TCM treatment, and 19.8% of the patients had only undergone surgery (indicating the early stage of cancer).

Table 1.

Demographic and Disease-Related Characteristics (n=2796)

Patient Characteristics n %
Age (years), [median (IQR)] 55(49–64)
Age (years)
 <50 739 (26.4)
 50–59 1084 (38.8)
 60–69 577 (20.6)
 ≥70 396 (14.2)
BMI (kg/m2), [median(IQR)] 22.6(20.4–24.8)
BMI (kg/m2)
 Underweight (<18.5) 267 (9.9)
 Normal weight (18.5–24) 1550 (57.4)
 Overweight (24–28) 693 (25.7)
 Obesity (≥28) 191 (7.1)
Sex
 Male 1216 (43.5)
 Female 1580 (56.5)
Race
 Han 2696 (97.2)
 Minority 78 (2.8)
Marital status
 Married 2529 (91.0)
 Others 250 (9.0)
Education level
 Primary school or below 754 (27.4)
 Middle and high schools 1345 (48.9)
 Junior college 364 (13.2)
 Bachelor’s degree or above 287 (10.4)
Employment status
 Unemployed 463 (16.9)
 Employed 449 (16.4)
 Peasantry 759 (27.7)
 Retiree 764 (27.9)
 Others 306 (11.2)
Type of insurance
 Employee’s medical insurance 1234 (45.4)
 Residents’ medical insurance 439 (16.2)
 Rural medical insurance 970 (35.7)
 Others 75 (2.8)
Smoking status
 Never 1838 (66.9)
 Current 253 (9.2)
 Former 655 (23.9)
Drinking history
 No 1780 (65.4)
 Yes 942 (34.6)
Hypertension
 No 2241 (83.0)
 Yes 458 (17.0)
Diabetes
 No 2447 (91.5)
 Yes 228 (8.5)
Coronary disease
 No 2552 (96.8)
 Yes 85 (3.2)
Family history of cancer
 No 2080 (75.5)
 Yes 674 (24.5)
Prior cancer treatments received
 No prior treatment 156 (6.3)
 Surgery only 488 (19.8)
 Chemotherapy only 233 (9.4)
 Radiotherapy only 59 (2.4)
 Surgery and chemotherapy, or surgery and radiotherapy, or chemotherapy and radiotherapy 1048 (42.5)
 Surgery and radiotherapy and chemotherapy 482 (19.5)
ECOG-PS
 0 465 (18.0)
 1 1777 (68.7)
 2 228 (8.8)
 3–4 117 (4.5)
Cancer primary site
 Lung 705 (25.2)
 Gynecological 378 (13.5)
 Breast 364 (13.0)
 Nasopharynx 241 (8.6)
 Colorectal 231 (8.3)
 Esophagus 205 (7.3)
 Hepatobiliary pancreas 143 (5.1)
 Gastric 102 (3.6)
 Thyroid 94 (3.4)
 Others 333 (11.9)
The reasons for the visit
 Symptom control 1661 (59.4)
 Functional recovery 1337 (47.8)
 Immune regulation 1550 (55.4)
 Tumor control 1242 (44.4)
 Therapy-induced toxicities reduction 596 (21.3)
 Other reasons 76 (2.7)

Abbreviations: IQR, interquartile range; BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group performance status.

Patient-Reported Outcomes (MDASI-TCM and EQ-5D-5L)

Among all patients, fatigue was the most frequently reported symptom (81.1%), followed by disturbed sleep (81.0%), dry mouth (78.2%), and memory difficulty (76.4%). Vomiting had the lowest incidence of reported symptoms (40.6%). Among patients with moderate-to-severe symptoms (scores of ≥4 on the MDASI-TCM’s 0–10 scale), disturbed sleep (50.3%) was the most prevalent, followed by fatigue (43.0%), dry mouth (41.2%), and feeling cold (38.6%). The median (IQR) number of moderate-to-severe symptoms reported was 5 (2–10). The most elevated self-reported symptom scores were observed for disturbed sleep (3.87±3.01), fatigue (3.38±2.68), and dry mouth (3.30±2.80). Feeling cold (3.06±2.80) and bitter taste (2.65±2.69) were the most elevated TCM-specific symptom scores. The mean patient-reported composite interference scores in the physical function subscale (WAW) and affective function subscale (REM) were 2.03±2.28 and 1.95±2.14 respectively, indicating broad symptom interference in cancer patients seeking TCM treatment (Table 2).

Table 2.

Mean MDASI-TCM Scores: Symptom Burden and Interference Severity

Items N Mean Score None Mild Moderate Severe
mean±SD n(%) n(%) n(%) n(%)
Core items
 Pain 2790 2.33±2.67 1117(40.0) 918(32.9) 487(17.5) 268(9.6)
 Fatigue (tiredness) 2790 3.38±2.68 527(18.9) 1064(38.1) 791(28.4) 408(14.6)
 Nausea 2774 1.70±2.41 1455(52.5) 779(28.1) 369(13.3) 170(6.1)
 Disturbed sleep 2785 3.87±3.01 530(19.0) 853(30.6) 775(27.8) 627(22.5)
 Distressed (upset) 2784 2.81±2.72 847(30.4) 951(34.2) 668(24.0) 317(11.4)
 Shortness of breath 2790 2.62±2.64 894(32.0) 1020(36.6) 579(20.8) 297(10.6)
 Problems remembering things 2788 2.90±2.48 652(23.4) 1124(40.3) 745(26.7) 267(9.6)
 Lack of appetite 2790 3.04±2.96 818(29.3) 953(34.2) 580(20.8) 439(15.7)
 Drowsy (sleepy) 2782 2.63±2.66 901(32.4) 1026(36.9) 559(20.1) 296(10.6)
 Dry mouth 2792 3.30±2.80 609(21.8) 1032(37.0) 718(25.7) 433(15.5)
 Sadness 2792 2.29±2.59 1102(39.5) 911(32.6) 553(19.8) 226(8.1)
 Vomiting 2786 1.43±2.32 1656(59.4) 681(24.4) 295(10.6) 154(5.5)
 Numbness or tingling 2785 2.29±2.64 1139(40.9) 876(31.5) 515(18.5) 255(9.2)
TCM-specific items
 Sweating 2766 2.60±2.67 909(32.9) 990(35.8) 578(20.9) 289(10.4)
 Feeling cold 2772 3.06±2.80 762(27.5) 940(33.9) 684(24.7) 386(13.9)
 Constipation 2790 2.33±2.81 1167(41.8) 865(31.0) 435(15.6) 323(11.6)
 Bitter taste 2791 2.65±2.69 908(32.5) 1003(35.9) 578(20.7) 302(10.8)
 Coughing 2791 2.25±2.55 1051(37.7) 1036(37.1) 462(16.6) 242(8.7)
 Palpitation (racing heartbeat) 2784 2.05±2.38 1130(40.6) 1008(36.2) 462(16.6) 184(6.6)
 Heat in palms or soles 2783 1.58±2.18 1393(50.1) 911(32.7) 364(13.1) 115(4.1)
Interfered items
 General activity 2796 1.94±2.42 1278(45.7) 917(32.8) 431(15.4) 170(6.1)
 Mood 2781 2.41±2.53 948(34.1) 1040(37.4) 564(20.3) 229(8.2)
 Work 2772 2.13±2.65 1176(42.4) 939(33.9) 420(15.2) 237(8.5)
 Relations with other people 2771 1.55±2.23 1474(53.2) 825(29.8) 356(12.8) 116(4.2)
 Walking 2791 2.06±2.63 1296(46.4) 806(28.9) 457(16.4) 232(8.3)
 Enjoyment of life 2787 1.90±2.50 1354(48.6) 811(29.1) 432(15.5) 190(6.8)
Total Interference
 Physical interference subscale (WAW) 2.03±2.28
 Affective interference subscale (REM) 1.95±2.14
 Number of moderate-to-severe symptoms reported, [median (IQR)] 5(2–10)

Abbreviations: WAW, walking, activity, work; REM, relations, enjoyment of life, mood.

The distribution of patients reporting difficulties in each dimension of the EQ-5D-5L is presented in Table 3 and Figure 1. The pain/discomfort dimension was the most commonly reported issue, affecting 69.1% of patients, followed by anxiety/depression (56.6%), mobility (34.3%), usual activities (28.1%), and self-care (15.1%). In total, 478 patients (17.2%) reported no issues across any of the five dimensions. The mean and median EQ-5D-5L index values for all cancer patients, applying the Chinese preference weights, were 0.81 and 0.89 respectively. The index values ranged from −0.391 to 1. Only 49 respondents (1.8%) had negative utilities, while 69.7% of the total sample reported utility values ≥0.8. The mean and median EQ-VAS scores were 69.42 and 70.0, respectively. Overall, self-reported EQ-VAS scores ranged from 10 to 100, with the three most frequently reported values being 80 (15.2%), 70 (11.9%), and 60 (11.7%).

Table 3.

Frequencies of Item Response in Each EQ-5D-5L Dimension, EQ-5D-5L Index Value and EQ-VAS Scores Reported by Participants

Dimensions N No Problem Slight Problem Moderate Problem Severe Problem Extreme Problem
Mobility, n (%) 2781 1826(65.7) 616(22.2) 213(7.7) 83(3.0) 43(1.5)
Self-care, n (%) 2775 2355(84.9) 266(9.6) 71(2.6) 39(1.4) 44(1.6)
Usual activities, n (%) 2780 1998(71.9) 535(19.2) 128(4.6) 63(2.3) 56(2.0)
Pain/discomfort, n (%) 2781 859(30.9) 1308(47.0) 401(14.4) 152(5.5) 61(2.2)
Anxiety/depression, n (%) 2775 1203(43.4) 1146(41.3) 317(11.4) 66(2.4) 43(1.5)
Mean (SD) Median (IQR)
EQ-VAS 69.42(18.51) 70.0(60.0–81.0)
EQ-5D-5L index value 0.81(0.23) 0.89(0.76–0.94)

Abbreviations: EQ-5D-5L, EuroQol-5Dimensions-5Levels; VAS, visual analog scale; SD, standard deviation; IQR, interquartile range.

Figure 1.

Figure 1

Patient-reported problems percentage in five levels of EQ-5D.

TCM Constitutional Types

A total of 2691 constitutional cases were analyzed, which is lower than the total number of patients due to missing items and the inability of some patients to receive a TCM constitutional diagnosis. Among these cases, 448 were classified as balanced constitution (16.6%), 674 as Yang-deficiency constitution (25.0%), 354 as dampness-heat constitution (13.2%), 318 as blood-stasis constitution (11.8%), 293 as Qi-deficiency constitution (10.9%), 233 as phlegm-dampness constitution (8.7%), 170 as Qi-stagnation constitution (6.3%), 112 as Yin-deficiency constitution (4.2%), and 89 as inherited-special constitution (3.3%) (Figure 2). The top three imbalanced TCM constitutional types across various cancers were predominantly Yang-deficiency, Dampness-heat, Blood-stasis, and Qi-deficiency. The distribution of TCM constitutional types among most cancer diagnoses showed statistical significance (P<0.05) (Table 4).

Figure 2.

Figure 2

The distribution of the TCM constitution types.

Table 4.

Comparative Analysis of TCM Constitution Types

Variables Cancer primary site
Lung, n(%) Nasopharynx, n(%) Hepatobiliary pancreas, n(%) Thyroid, n(%) Colorectal, n(%) Gynecological, n(%) Breast, n(%) Esophagus, n(%) Gastric, n(%) Others, n(%)
TCM Constitutional type
 Balanced 120(17.7) 34(14.5) 26(19.0) 11(12.2) 41(18.3) 54(14.9) 45(13.0) 37(18.7) 16(16.3) 64(19.9)
 Qi-deficiency 97(14.3)* 17(7.2) 17(12.4)* 12(13.3)* 14(6.3) 33(9.1) 39(11.2)* 13(6.6) 10(10.2) 41(12.7)
 Yang-deficiency 161(23.7)* 55(23.4)* 30(21.9)* 22(24.4)* 53(23.7)* 103(28.5)* 91(26.2)* 61(30.8)* 34(34.7)* 64(19.9)*
 Yin-deficiency 31(4.6) 8(3.4) 1(0.7) 2(2.2) 6(2.7) 19(5.2) 27(7.8) 1(0.5) 4(4.1) 13(4.0)
 Phlegm-dampness 63(9.3) 38(16.2)* 7(5.1) 9(10.0) 13(5.8) 17(4.7) 18(5.2) 15(7.6) 11(11.2)* 42(13.0)*
 Dampness-heat 70(10.3)* 35(14.9)* 27(19.7)* 12(13.3)* 49(21.9)* 55(15.2)* 36(10.4) 20(10.1)* 11(11.2)* 39(12.1)*
 Blood-stasis 68(10.0) 22(9.4) 13(9.5) 14(15.6)* 30(13.4)* 54(14.9)* 60(17.3)* 25(12.6)* 4(4.1) 28(8.7)
 Qi-stagnation 50(7.4) 17(7.2) 10(7.3) 4(4.4) 6(2.7) 17(4.7) 23(6.6) 20(10.1)* 4(4.1) 19(5.9)
 Inherited-special 18(2.7) 9(3.8) 6(4.4) 4(4.4) 12(5.4) 10(2.8) 8(2.3) 6(3.0) 4(4.1) 12(3.7)
 Total 678(100.0) 235(100.0) 137(100.0) 90(100.0) 224(100.0) 362(100.0) 347(100.0) 198(100.0) 98(100.0) 322(100.0)
χ2 22.47 23.77 13.63 4.64 31.87 19.51 35.30 20.72 11.03 19.09
P value 0.004 0.003 0.092 0.795 <0.001 0.012 <0.001 0.008 0.200 0.014

Notes: Statistically significant values are given in bold (P< 0.05); *The top three imbalanced TCM Constitutional types in each cancer type.

Discussion

Cancer patients opting for TCM were predominantly female, middle-aged, and exhibited good performance status, similar to a survey conducted on patients from a hospital in Australia.30 Most patients visiting the TCM clinic expressed willingness to boost their immune system and alleviate cancer-related symptoms, predominantly fatigue, disturbed sleep, poor appetite, and dry mouth. These symptoms were measured via two commonly used PROs instruments, offering a comprehensive assessment of symptom burden and HRQoL. With the largest sample size of cancer patients treated with TCM to date, our findings reaffirmed that TCM plays a crucial role in the supportive care of various cancer types and its broad acceptance across different age groups among cancer patients.

The high prevalence of breast and gynecological cancers among TCM patients may be attributed to the high proportion of females and younger age. However, lung cancer remains the predominant cancer type, consistent with findings from general cancer population studies.40,41 The adverse effects of conventional cancer therapies often lead to a deterioration in patients’ QoL,42 whereas, TCM is widely acknowledged for its ability to alleviate treatment-related side effects and improve QoL.43 Consequently, patients seeking initial consultation at TCM rehabilitation clinics often exhibit lower health utility scores. It is commonly believed that TCM possesses advantages as a way of supportive or palliative care to alleviate cancer-related symptoms during terminal stages, particularly when Western medical treatments provide no further options. However, recent studies indicated that TCM can play a significant role throughout the entire course of cancer treatment, including recovery stages after surgery, chemotherapy, or radiotherapy, rather than solely during the terminal stage.18,44 For example, 19.8% of early-stage cancer patients with high EQ-5D-5L scores only received surgery, with their rehabilitation goals often focused on returning to normal life and maintaining employment. The extensive sample size of our study encompassed participants from all age groups, diagnoses, and stages of cancer, contributing to a robust and unbiased estimation of the general cancer population seeking TCM rehabilitation.

Cancer-related fatigue (CRF) was the most prevalent symptom that cannot be relieved by sleep or rest.45,46 It substantially interferes with daily activities and diminishes patients’ QoL. Currently, no standardized approaches exist for the treatment of CRF. Sleep disturbance was the most elevated self-reported symptom score and commonly treated with pharmacological treatments, including benzodiazepines, antidepressants, and antihistamines. However, the daily use of sleep-promoting medications is associated with various side effects, including drowsiness, dizziness, memory impairment, and an increased risk of psychiatric disorders.47,48 Many cancer patients seek traditional, complementary, and integrative medicine (TCIM) to reduce the toxicity and enhance the therapeutic effects of Western medicine, aiming to address a myriad of unmet needs.49 Integrating TCM with conventional cancer therapies could provide a holistic approach to improving patient outcomes, particularly in managing cancer-related symptoms and enhancing overall quality of life. TCM, such as traditional herbal medicine and acupuncture, is widely integrated into oncology departments in hospitals across China, alongside conventional cancer treatments, and has increasingly been incorporated into the management of cancer-related symptoms.50,51 Consequently, there is a pressing need for further clinical research on TCM treatments, improved evidence-based education, and more patient-centered, accessible TCM therapies for cancer patients.29

Constitution classification is the basis and core content of TCM.52 This study revealed that approximately 83.4% of cancer patients have a deviation in TCM constitution. Among these deviations, Yang-deficiency, Qi-deficiency, and Phlegm-dampness were identified as the most prevalent across various cancer types. However, the specific patterns of TCM constitutional deviations across cancer types are different, with Yang-deficiency and Qi-deficiency being more prevalent in lung and liver cancers,53,54 while Qi-stagnation and Yin-deficiency are more common in breast cancer.55,56 These differences may be influenced by biological factors, such as tumor microenvironment and metabolic dysregulation, as well as cultural factors, including lifestyle and dietary habits.57 In previous studies, Yang-deficiency was significantly associated with CRF in cancer patients,58,59 this may be attributed to disruption of mitochondrial metabolic activity.60 Additionally, increased levels of inflammatory cytokines may contribute to fatigue by affecting the hypothalamus-pituitary-adrenal (HPA) axis, thereby inducing Yang-deficiency.61 Dampness-heat constitution was a risk factor for chemotherapy-induced nausea and vomiting (CINV).55 The CCMQ could serve as a clinical tool to identify cancer patients predisposed to severe cancer-related symptoms, providing TCM doctors with a basis for selecting an appropriate treatment based on TCM constitution. For instance, in cases of Qi-deficiency constitution, Panax ginseng is commonly selected as the main Chinese herbal medicine incorporated into TCM prescriptions.54 Similarly, Yang-deficiency constitution can be addressed through nonpharmaceutical interventions such as acupuncture and tai chi.62 With the distribution pattern of TCM constitution in cancer patients provided in our analysis, Chinese medicine practitioners could conduct personalized therapy according to the TCM constitutional type, so as to adjust biased constitutions.

This study has several limitations. First, although the response rate exceeded 90%, which supports the reliability of the study findings, the presence of non-respondents and missing data means that not all participants were evaluated. However, the high response rate and robust sample size still provides valuable insights into the research question. Second, the study was conducted at a single cancer hospital in China. Despite the large sample size, which illustrated patient heterogeneity, the potential for selection bias cannot be excluded. Thus, future research should involve multi-center studies to improve the generalizability of the findings and minimize selection bias. Third, in this study, due to self-reported by patients, no clinical outcomes were collected. While PROs are inherently subjective, they often provide more accurate reflections of symptoms and functional status than objective clinical measurements, particularly in assessing daily functions.63 Additionally, the inherent limitations of a baseline data analysis must be acknowledged, as the data could not reflect changes in symptom burden longitudinally nor support causal analysis. Future studies are warranted to profile symptom trajectories in cancer patients undergoing TCM treatment and examine their association with clinical outcomes.

Conclusion

In conclusion, TCM is not merely focused on palliative care; it plays a significant role throughout the entire course of cancer treatment, not only in the terminal stages. Cancer patients seeking TCM rehabilitation are a general cancer population across all ages, diagnoses, and disease stages. These patients often experience a heavy symptom burden and a poor HRQoL. Therefore, it is recommended to enhance the capabilities of TCM rehabilitation services and develop evidence-based TCM practice strategies in cancer hospitals. Furthermore, TCM rehabilitation knowledge among cancer patients and oncologists should be improved, thereby maximizing the therapeutic benefits of TCM in cancer rehabilitation. These findings can provide a foundation for future research and decision-making in supportive care for cancer patients undergoing TCM treatment.

Acknowledgments

We thank all the patients involved in this study and thank Huazhi Liang, Yingchu A, and Jingyi Lu for their data entry work.

Funding Statement

This study was supported by the Fundamental Research Funds for the Central public welfare research institutes(grant number: ZZ15-WT-05) and Sichuan Science and Technology Program(grant number: 2023YFS0328).

Abbreviations

TCM, Traditional Chinese Medicine; PROs, Patient-reported outcomes; PROM, Patient-reported outcome measure; HRQoL, health-related quality of life; MDASI-TCM, MD Anderson Symptom Inventory for Traditional Chinese Medicine; EQ-5D-5L, EuroQol-5Dimensions-5Levels; VAS, Visual analog scale; CCMQ, Constitution in Chinese Medicine Questionnaire; CAM, Complementary and alternative medicine; CHM, Chinese herbal medicine; BMI, Body mass index; ECOG-PS, Eastern Cooperative Oncology Group score; REM, Relations with others, enjoyment of life, and mood; WAW, Walking, general activity, and work; SD, Standard deviation; IQR, Interquartile range; CRF, Cancer-related fatigue; TCIM, Traditional, complementary, and integrative medicine; CINV, Chemotherapy-induced nausea and vomiting.

Data Sharing Statement

The data and materials in this study are available from the corresponding author upon reasonable request.

Ethics Approval and Informed Consent

The study was reviewed and approved by the Ethics Committee for Medical Research and New Medical Technology of Sichuan Cancer Hospital (Approval Number: SCCHEC-02-2021-048 and KY-2021-004-03). The study complies with the Declaration of Helsinki.

Consent for Publication

All data sources and individual person’s datum submitted were accepted for publication.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.

References

  • 1.Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–263. doi: 10.3322/caac.21834 [DOI] [PubMed] [Google Scholar]
  • 2.Sonkin D, Thomas A, Teicher BA. Cancer treatments: past, present, and future. Cancer Genet. 2024;286–287:18–24. doi: 10.1016/j.cancergen.2024.06.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Cleeland CS, Sloan JA; ASCPRO Organizing Group. Assessing the Symptoms of Cancer Using Patient-Reported Outcomes(ASCPRO): searching for standards. J Pain Symptom Manage. 2010;39(6):1077–1085. doi: 10.1016/j.jpainsymman.2009.05.025 [DOI] [PubMed] [Google Scholar]
  • 4.Dantzer R, Meagher MW, Cleeland CS. Translational approaches to treatment-induced symptoms in cancer patients. Nat Rev Clin Oncol. 2012;9(7):414–426. doi: 10.1038/nrclinonc.2012.88 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Cleeland CS, Zhao F, Chang VT, et al. The symptom burden of cancer: evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study. Cancer. 2013;119(24):4333–4340. doi: 10.1002/cncr.28376 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Basch E, Schrag D, Henson S, et al. Effect of electronic symptom monitoring on patient-reported outcomes among patients with metastatic cancer: a randomized clinical trial. JAMA. 2022;327(24):2413–2422. doi: 10.1001/jama.2022.9265 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Denis F, Basch E, Septans AL, et al. Two-year survival comparing web-based symptom monitoring vs routine surveillance following treatment for lung cancer. JAMA. 2019;321(3):306–307. doi: 10.1001/jama.2018.18085 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.He Y, Pang Y, Su Z, et al. Symptom burden, psychological distress, and symptom management status in hospitalized patients with advanced cancer: a multicenter study in China. ESMO Open. 2022;7(6):100595. doi: 10.1016/j.esmoop.2022.100595 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Zeng YS, Wang C, Ward KE, Hume AL. Complementary and alternative medicine in hospice and palliative care: a systematic review. J Pain Symptom Manage. 2018;56(5):781–794.e4. doi: 10.1016/j.jpainsymman.2018.07.016 [DOI] [PubMed] [Google Scholar]
  • 10.Caballero-Gallardo K, Quintero-Rincón P, Olivero-Verbel J. Aromatherapy and essential oils: holistic strategies in complementary and alternative medicine for integral wellbeing. Plants. 2025;14(3):400. doi: 10.3390/plants14030400 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Liu J, Wang S, Zhang Y, Fan HT, Lin HS. Traditional Chinese medicine and cancer: history, present situation, and development. Thorac Cancer. 2015;6(5):561–569. doi: 10.1111/1759-7714.12270 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Zhang X, Qiu H, Li C, Cai P, Qi F. The positive role of traditional Chinese medicine as an adjunctive therapy for cancer. Biosci Trends. 2021;15(5):283–298. doi: 10.5582/bst.2021.01318 [DOI] [PubMed] [Google Scholar]
  • 13.Chen G, Qiao TT, Ding H, et al. Use of Chinese herbal medicine therapies in comprehensive hospitals in central China: a parallel survey in cancer patients and clinicians. J Huazhong Univ Sci Technolog Med Sci. 2015;35(6):808–814. doi: 10.1007/s11596-015-1511-5 [DOI] [PubMed] [Google Scholar]
  • 14.McQuade JL, Meng Z, Chen Z, et al. Utilization of and attitudes towards traditional Chinese medicine therapies in a Chinese cancer hospital: a survey of patients and physicians. Evid Based Complement Alternat Med. 2012;2012:504507. doi: 10.1155/2012/504507 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Liu TG, Xiong SQ, Yan Y, Zhu H, Yi C. Use of Chinese herb medicine in cancer patients: a survey in southwestern China. Evid Based Complement Alternat Med. 2012;2012:769042. doi: 10.1155/2012/769042 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Yu HY, Wang XQ, Zhang Y, Liu J, Lin HS. Application status of Chinese medicine on cancer rehabilitation: a preliminary questionnaire survey. Chin J Integr Med. 2020;26(12):890–896. doi: 10.1007/s11655-020-3280-7 [DOI] [PubMed] [Google Scholar]
  • 17.Zhu X, Wu Z, Cao Y, Gao R, Zhang X, Li J. Efficacy and safety of TCM therapies combined with hyperthermic intraperitoneal chemotherapy for peritoneal metastasis of gastric cancer: a protocol for systematic review and meta-analysis. Medicine. 2021;100(4). doi: 10.1097/MD.0000000000024337 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Qi F, Zhao L, Zhou A, et al. The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer. Biosci Trends. 2015;9(1):16–34. doi: 10.5582/bst.2015.01019 [DOI] [PubMed] [Google Scholar]
  • 19.Wang S, Long S, Deng Z, Wu W. Positive role of Chinese Herbal Medicine in cancer immune regulation. Am J Chin Med. 2020;48(7):1577–1592. doi: 10.1142/S0192415X20500780 [DOI] [PubMed] [Google Scholar]
  • 20.Kiefer D, Pantuso T. Panax ginseng. Am Fam Physician. 2003;68(8):1539–1542. [PubMed] [Google Scholar]
  • 21.Chen Z, Liu L, Gao C, et al. Astragali Radix(Huangqi): a promising edible immunomodulatory herbal medicine. J Ethnopharmacol. 2020;258:112895. doi: 10.1016/j.jep.2020.112895 [DOI] [PubMed] [Google Scholar]
  • 22.Hengrui L. Toxic medicine used in traditional Chinese medicine for cancer treatment: are ion channels involved? J Tradit Chin Med. 2022;42(6):1019–1022. doi: 10.19852/j.cnki.jtcm.20220815.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Zhang XW, Hou WB, Pu FL, et al. Acupuncture for cancer-related conditions: an overview of systematic reviews. Phytomedicine. 2022;106:154430. doi: 10.1016/j.phymed.2022.154430 [DOI] [PubMed] [Google Scholar]
  • 24.Garland SN, Xie SX, DuHamel K, et al. Acupuncture versus cognitive behavioral therapy for Insomnia in cancer survivors: a randomized clinical trial. J Natl Cancer Inst. 2019;111(12):1323–1331. doi: 10.1093/jnci/djz050 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.He Y, Guo X, May BH, et al. Clinical evidence for association of acupuncture and acupressure with improved cancer pain: a systematic review and meta-analysis. JAMA Oncol. 2020;6(2):271–278. doi: 10.1001/jamaoncol.2019.5233 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Abuelgasim KA, Alsharhan Y, Alenzi T, Alhazzani A, Ali YZ, Jazieh AR. The use of complementary and alternative medicine by patients with cancer: a cross-sectional survey in Saudi Arabia. BMC Complement Altern Med. 2018;18(1):88. doi: 10.1186/s12906-018-2150-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Wode K, Henriksson R, Sharp L, Stoltenberg A, Hök Nordberg J. Cancer patients’ use of complementary and alternative medicine in Sweden: a cross-sectional study. BMC Complement Altern Med. 2019;19:62. doi: 10.1186/s12906-019-2452-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Bauml JM, Chokshi S, Schapira MM, et al. Do attitudes and beliefs regarding complementary and alternative medicine impact its use among patients with cancer? A cross-sectional survey. Cancer. 2015;121(14):2431–2438. doi: 10.1002/cncr.29173 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Sun L, Mao JJ, Vertosick E, Seluzicki C, Yang Y. Evaluating cancer patients’ expectations and barriers toward traditional Chinese medicine utilization in China: a patient-support group-based cross-sectional survey. Integr Cancer Ther. 2018;17(3):885–893. doi: 10.1177/1534735418777117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Grant SJ, Kwon K, Naehrig D, Asher R, Lacey J. Characteristics and symptom burden of patients accessing acupuncture services at a cancer hospital. Integr Cancer Ther. 2021;20:15347354211002253. doi: 10.1177/15347354211002253 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Liu L, Wei Y, Teng Y, Yan J, Li F, Chen Y. Health-related quality of life and utility scores of lung cancer patients treated with traditional Chinese medicine in China. Patient Prefer Adherence. 2022;16:297–306. doi: 10.2147/PPA.S344622 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Mao JJ, Farrar JT, Armstrong K, Donahue A, Ngo J, Bowman MA. De qi: Chinese acupuncture patients’ experiences and beliefs regarding acupuncture needling sensation–an exploratory survey. Acupunct Med. 2007;25(4):158–165. doi: 10.1136/aim.25.4.158 [DOI] [PubMed] [Google Scholar]
  • 33.Li Z, Shi Q, Liu M, et al. Validation and application of the MD Anderson Symptom Inventory for traditional Chinese medicine (MDASI-TCM). J Natl Cancer Inst Monogr. 2017;2017(52). doi: 10.1093/jncimonographs/lgx010 [DOI] [PubMed] [Google Scholar]
  • 34.Xue D, Han S, Jiang S, et al. Comprehensive geriatric assessment and traditional Chinese medicine intervention benefit symptom control in elderly patients with advanced non-small cell lung cancer. Med Oncol. 2015;32(4):114. doi: 10.1007/s12032-015-0563-5 [DOI] [PubMed] [Google Scholar]
  • 35.Zhao Y, Wang XS, Li PP. Investigation of common symptoms of cancer and reliability analysis. Chin J Integr Med. 2007;13(3):195–199. doi: 10.1007/s11655-007-0195-5 [DOI] [PubMed] [Google Scholar]
  • 36.Huepenbecker SP, Iniesta MD, Wang XS, et al. Longitudinal perioperative patient-reported outcomes in open compared to minimally invasive hysterectomy. Am J Clin Exp Obstet Gynecol. 2024;230(2):241–e1. doi: 10.1016/j.ajog.2023.10.012 [DOI] [PubMed] [Google Scholar]
  • 37.Luo N, Li M, Liu GG, Lloyd A, de Charro F, Herdman M. Developing the Chinese version of the new 5-level EQ-5D descriptive system: the response scaling approach. Qual Life Res. 2013;22(4):885–890. doi: 10.1007/s11136-012-0200-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Luo N, Liu G, Li M, Guan H, Jin X, Rand-Hendriksen K. Estimating an EQ-5D-5L value set for China. Value Health. 2017;20(4):662–669. doi: 10.1016/j.jval.2016.11.016 [DOI] [PubMed] [Google Scholar]
  • 39.Liu SJ, Zhou CC, Lin QS, et al. Study on simplification of traditional Chinese medicine constitution classification and distinguishing scale. J Guangzhou Univ TCM. 2021;38(8):1734–1739. doi: 10.13359/j.cnki.gzxbtcm.2021.08.035 [DOI] [Google Scholar]
  • 40.Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi: 10.3322/caac.21338 [DOI] [PubMed] [Google Scholar]
  • 41.Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J. 2022;135(5):584–590. doi: 10.1097/CM9.0000000000002108 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Ko CY, Maggard M, Livingston EH. Evaluating health utility in patients with melanoma, breast cancer, colon cancer, and lung cancer: a nationwide, population-based assessment. J Surg Res. 2003;114(1):1–5. doi: 10.1016/s0022-4804(03)00167-7 [DOI] [PubMed] [Google Scholar]
  • 43.Balducci L, Dolan D. Palliative care of cancer in the older patient. Curr Oncol Rep. 2016;18(12):70. doi: 10.1007/s11912-016-0557-2 [DOI] [PubMed] [Google Scholar]
  • 44.Zhou J, Zhou T, Jiang M, et al. Research progress on synergistic anti-tumor mechanisms of compounds in traditional Chinese medicine. J Tradit Chin Med. 2014;34(1):100–105. doi: 10.1016/s0254-6272(14)60062-5 [DOI] [PubMed] [Google Scholar]
  • 45.Berger AM, Mooney K, Alvarez-Perez A, et al. Cancer-related fatigue, version 2.2015. J Natl Compr Canc Netw. 2015;13(8):1012–1039. doi: 10.6004/jnccn.2015.0122 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Cella D, Davis K, Breitbart W, Curt G; Fatigue Coalition. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol. 2001;19(14):3385–3391. doi: 10.1200/JCO.2001.19.14.3385 [DOI] [PubMed] [Google Scholar]
  • 47.Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4(5):487–504. [PMC free article] [PubMed] [Google Scholar]
  • 48.Loh KP, Burhenn P, Hurria A, Zachariah F, Mohile SG. How do I best manage insomnia and other sleep disorders in older adults with cancer? J Geriatr Oncol. 2016;7(6):413–421. doi: 10.1016/j.jgo.2016.05.003 [DOI] [PubMed] [Google Scholar]
  • 49.Mao JJ, Pillai GG, Andrade CJ, et al. Integrative oncology: addressing the global challenges of cancer prevention and treatment. CA A Cancer J Clinicians. 2022;72(2):144–164. doi: 10.3322/caac.21706 [DOI] [PubMed] [Google Scholar]
  • 50.Yang J, Li Y, Chau CI, et al. Efficacy and safety of traditional Chinese medicine for cancer-related fatigue: a systematic literature review of randomized controlled trials. Chin Med. 2023;18(1):142. doi: 10.1186/s13020-023-00849-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Zhang J, Zhang Z, Huang S, et al. Acupuncture for cancer-related insomnia: a systematic review and meta-analysis. Phytomedicine. 2022;102:154160. doi: 10.1016/j.phymed.2022.154160 [DOI] [PubMed] [Google Scholar]
  • 52.Li L, Wang Z, Wang J, Zheng Y, Li Y, Wang Q. Enlightenment about using TCM constitutions for individualized medicine and construction of Chinese-style precision medicine: research progress with TCM constitutions. Sci China Life Sci. 2021;64(12):2092–2099. doi: 10.1007/s11427-020-1872-7 [DOI] [PubMed] [Google Scholar]
  • 53.Yu X, Yan L, Lan Q, et al. Correlation between TCM constitutional types and lung carcinoma in various geographical areas: a systematic review and meta-analysis. Contrast Media Mol Imaging. 2022;2022:5660231. doi: 10.1155/2022/5660231 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Hou Z, Song F, Xing J, Zheng Z, Liu S, Liu Z. Comprehensive fecal metabolomics and gut microbiota for the evaluation of the mechanism of panax ginseng in the treatment of qi-deficiency liver cancer. J Ethnopharmacol. 2022;292:115222. doi: 10.1016/j.jep.2022.115222 [DOI] [PubMed] [Google Scholar]
  • 55.Liu Y, Pan T, Zou W, et al. Relationship between traditional Chinese medicine constitutional types with chemotherapy-induced nausea and vomiting in patients with breast cancer: an observational study. BMC Complement Altern Med. 2016;16:451. doi: 10.1186/s12906-016-1415-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Lin SCA, Chu PY, Chen LL, Su YC, Wang SM. The prevalence rate of deviations in body constitutions and related factors in follow-up stage breast cancer patients-a nationwide study. Complement Ther Med. 2017;32:49–55. doi: 10.1016/j.ctim.2017.03.013 [DOI] [PubMed] [Google Scholar]
  • 57.Liang X, Wang Q, Jiang Z, et al. Clinical research linking traditional Chinese medicine constitution types with diseases: a literature review of 1639 observational studies. J Tradit Chin Med. 2020;40(4):690–702. doi: 10.19852/j.cnki.jtcm.2020.04.019 [DOI] [PubMed] [Google Scholar]
  • 58.Deng SM, Chiu AF, Wu SC, et al. Association between cancer-related fatigue and traditional Chinese medicine body constitution in female patients with breast cancer. J Tradit Complement Med. 2020;11(1):62–67. doi: 10.1016/j.jtcme.2020.08.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Yeh MH, Chao CH, Koo M, Chen CY, Yeh CC, Li TM. Association of traditional Chinese medicine body constitution and moderate-to-severe cancer-related fatigue in cancer patients. Complement Ther Med. 2019;43:44–48. doi: 10.1016/j.ctim.2019.01.004 [DOI] [PubMed] [Google Scholar]
  • 60.Leong PK, Wong HS, Chen J, Ko KM. Yang/qi invigoration: an herbal therapy for chronic fatigue syndrome with yang deficiency? Evid Based Complement Alternat Med. 2015;2015:945901. doi: 10.1155/2015/945901 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Bower JE. Cancer-related fatigue--mechanisms, risk factors, and treatments. Nat Rev Clin Oncol. 2014;11(10):597–609. doi: 10.1038/nrclinonc.2014.127 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Huang SM, Chien LY, Tai CJ, Chen PH, Lien PJ, Tai CJ. Effects of symptoms and complementary and alternative medicine use on the yang deficiency pattern among breast cancer patients receiving chemotherapy. Complement Ther Med. 2015;23(2):233–241. doi: 10.1016/j.ctim.2015.01.004 [DOI] [PubMed] [Google Scholar]
  • 63.Basch E. Patient-reported outcomes - harnessing patients’ voices to improve clinical care. N Engl J Med. 2017;376(2):105–108. doi: 10.1056/NEJMp1611252 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The data and materials in this study are available from the corresponding author upon reasonable request.


Articles from Patient preference and adherence are provided here courtesy of Dove Press

RESOURCES